Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 12 | 2024 | 663 | 3.120 |
Why?
|
| Medicaid | 15 | 2025 | 335 | 3.050 |
Why?
|
| Atrial Fibrillation | 7 | 2024 | 795 | 2.600 |
Why?
|
| Accountable Care Organizations | 8 | 2025 | 57 | 2.440 |
Why?
|
| Anticoagulants | 8 | 2024 | 485 | 2.300 |
Why?
|
| Medicare | 10 | 2024 | 601 | 1.690 |
Why?
|
| Stroke | 5 | 2023 | 1135 | 1.600 |
Why?
|
| United States | 30 | 2025 | 7492 | 1.380 |
Why?
|
| Homes for the Aged | 2 | 2021 | 164 | 1.230 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 549 | 1.200 |
Why?
|
| Memantine | 2 | 2024 | 23 | 1.100 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 248 | 0.970 |
Why?
|
| Aged | 21 | 2024 | 13285 | 0.960 |
Why?
|
| Cross-Sectional Studies | 13 | 2025 | 2461 | 0.950 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 84 | 0.900 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2021 | 14 | 0.890 |
Why?
|
| Dementia | 2 | 2024 | 247 | 0.880 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 36 | 0.860 |
Why?
|
| Hospices | 1 | 2023 | 32 | 0.850 |
Why?
|
| Inappropriate Prescribing | 2 | 2021 | 67 | 0.840 |
Why?
|
| Hospice Care | 1 | 2023 | 59 | 0.820 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.810 |
Why?
|
| Humans | 47 | 2025 | 59284 | 0.800 |
Why?
|
| Warfarin | 2 | 2020 | 108 | 0.780 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 712 | 0.740 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 114 | 0.730 |
Why?
|
| Medicare Part C | 1 | 2021 | 15 | 0.730 |
Why?
|
| Administration, Oral | 4 | 2024 | 345 | 0.720 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 5063 | 0.690 |
Why?
|
| Rivaroxaban | 1 | 2018 | 21 | 0.630 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 312 | 0.630 |
Why?
|
| Dabigatran | 1 | 2018 | 23 | 0.630 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 298 | 0.630 |
Why?
|
| Italy | 6 | 2021 | 62 | 0.610 |
Why?
|
| Brain Ischemia | 2 | 2019 | 403 | 0.610 |
Why?
|
| Metformin | 1 | 2019 | 67 | 0.600 |
Why?
|
| Massachusetts | 8 | 2025 | 2083 | 0.590 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 11 | 0.590 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.590 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 153 | 0.580 |
Why?
|
| Male | 24 | 2025 | 27480 | 0.560 |
Why?
|
| Hospitalization | 6 | 2023 | 1278 | 0.560 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 45 | 0.560 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 211 | 0.550 |
Why?
|
| Ambulatory Care | 1 | 2019 | 299 | 0.550 |
Why?
|
| Female | 24 | 2025 | 30798 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 446 | 0.520 |
Why?
|
| Cohort Studies | 5 | 2024 | 2435 | 0.510 |
Why?
|
| General Practitioners | 1 | 2015 | 15 | 0.500 |
Why?
|
| Hemorrhage | 3 | 2024 | 276 | 0.480 |
Why?
|
| Drug Utilization | 3 | 2021 | 223 | 0.470 |
Why?
|
| Nurses | 1 | 2015 | 103 | 0.460 |
Why?
|
| Retrospective Studies | 7 | 2024 | 5967 | 0.450 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 44 | 0.440 |
Why?
|
| Cost of Illness | 1 | 2014 | 154 | 0.430 |
Why?
|
| Biopsy | 1 | 2014 | 373 | 0.420 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 672 | 0.420 |
Why?
|
| Patient Care Team | 1 | 2015 | 324 | 0.410 |
Why?
|
| Managed Care Programs | 2 | 2025 | 93 | 0.410 |
Why?
|
| Health Equity | 2 | 2023 | 42 | 0.400 |
Why?
|
| Mammography | 1 | 2014 | 272 | 0.390 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 262 | 0.380 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5141 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 558 | 0.370 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 67 | 0.360 |
Why?
|
| Quality of Life | 1 | 2017 | 1108 | 0.350 |
Why?
|
| Medication Adherence | 3 | 2022 | 255 | 0.330 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 254 | 0.330 |
Why?
|
| Mass Screening | 1 | 2014 | 643 | 0.320 |
Why?
|
| Cognition Disorders | 2 | 2021 | 217 | 0.300 |
Why?
|
| Sex Factors | 3 | 2021 | 959 | 0.290 |
Why?
|
| Middle Aged | 11 | 2025 | 16232 | 0.280 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 781 | 0.270 |
Why?
|
| Age Factors | 3 | 2021 | 1518 | 0.260 |
Why?
|
| Child | 4 | 2025 | 4298 | 0.260 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1126 | 0.250 |
Why?
|
| Social Determinants of Health | 3 | 2022 | 114 | 0.250 |
Why?
|
| Time Factors | 3 | 2019 | 3567 | 0.250 |
Why?
|
| Health Care Reform | 2 | 2023 | 88 | 0.250 |
Why?
|
| Residence Characteristics | 3 | 2023 | 224 | 0.240 |
Why?
|
| Nurse Administrators | 1 | 2024 | 19 | 0.240 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 46 | 0.230 |
Why?
|
| Health Care Costs | 2 | 2017 | 200 | 0.230 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 1019 | 0.230 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2584 | 0.230 |
Why?
|
| Adult | 9 | 2025 | 15729 | 0.220 |
Why?
|
| Qualitative Research | 2 | 2025 | 605 | 0.220 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 563 | 0.220 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.210 |
Why?
|
| Deprescriptions | 1 | 2023 | 22 | 0.210 |
Why?
|
| Comorbidity | 3 | 2021 | 1084 | 0.210 |
Why?
|
| Social Responsibility | 1 | 2022 | 11 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 93 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1224 | 0.200 |
Why?
|
| Racism | 1 | 2023 | 81 | 0.200 |
Why?
|
| Primary Health Care | 2 | 2025 | 645 | 0.200 |
Why?
|
| Risk Factors | 2 | 2023 | 4997 | 0.190 |
Why?
|
| Life Expectancy | 1 | 2021 | 32 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 62 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 739 | 0.190 |
Why?
|
| Drug Repositioning | 1 | 2021 | 6 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 141 | 0.190 |
Why?
|
| Young Adult | 5 | 2025 | 4318 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 328 | 0.170 |
Why?
|
| Cognition | 1 | 2023 | 459 | 0.170 |
Why?
|
| Anticonvulsants | 1 | 2020 | 94 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 42 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 315 | 0.160 |
Why?
|
| Epilepsy | 1 | 2020 | 108 | 0.160 |
Why?
|
| Thromboembolism | 1 | 2018 | 70 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 59 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 188 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 266 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 542 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2019 | 278 | 0.150 |
Why?
|
| Adolescent | 4 | 2025 | 5914 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 152 | 0.150 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 19 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 90 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 270 | 0.150 |
Why?
|
| Physicians | 1 | 2023 | 436 | 0.150 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 35 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2021 | 891 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 105 | 0.140 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 56 | 0.140 |
Why?
|
| Disability Evaluation | 1 | 2017 | 214 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 149 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 61 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2015 | 73 | 0.120 |
Why?
|
| Physician-Nurse Relations | 1 | 2015 | 26 | 0.120 |
Why?
|
| Schizophrenia | 1 | 2017 | 256 | 0.120 |
Why?
|
| Pneumonia | 1 | 2017 | 263 | 0.120 |
Why?
|
| Medicine | 1 | 2015 | 56 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 74 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 131 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2014 | 98 | 0.110 |
Why?
|
| Length of Stay | 1 | 2017 | 765 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 256 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 493 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2021 | 763 | 0.110 |
Why?
|
| Health Promotion | 1 | 2017 | 491 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 417 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2025 | 483 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 326 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 855 | 0.100 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 80 | 0.080 |
Why?
|
| Pharmacists | 2 | 2023 | 123 | 0.080 |
Why?
|
| Quality of Health Care | 2 | 2023 | 519 | 0.080 |
Why?
|
| Food Services | 1 | 2025 | 28 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2024 | 188 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 214 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 72 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 78 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 91 | 0.050 |
Why?
|
| Income | 1 | 2023 | 160 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 917 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 286 | 0.050 |
Why?
|
| Health Personnel | 1 | 2025 | 340 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 40 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2021 | 38 | 0.050 |
Why?
|
| Administrative Personnel | 1 | 2021 | 33 | 0.050 |
Why?
|
| Palliative Care | 1 | 2023 | 202 | 0.050 |
Why?
|
| Medicare Part D | 1 | 2020 | 35 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 787 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2025 | 1837 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 219 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 252 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 424 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 552 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 314 | 0.040 |
Why?
|
| Senior Centers | 1 | 2017 | 1 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 350 | 0.040 |
Why?
|
| Injections | 1 | 2017 | 79 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 565 | 0.040 |
Why?
|
| Taiwan | 1 | 2017 | 8 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 99 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 802 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 281 | 0.030 |
Why?
|
| Health Resources | 1 | 2017 | 88 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 106 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 132 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 419 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 387 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 606 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 159 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1279 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 810 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1232 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 52 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 337 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 926 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 371 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 295 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 689 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 837 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1039 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2323 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1907 | 0.020 |
Why?
|